Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Diabetic Nephropathies: early-phase trial registry
6 of 13 indexed Diabetic Nephropathies trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,315 of 28,707 conditions by registered trial count.
13 US clinical trials · 6 currently recruiting · #1,315 of 28,707 conditions by registered trial count
Diabetic Nephropathies: 13 US clinical trials tracked, 6 recruiting.
Diabetic Nephropathies is the subject of 13 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is University of Colorado, Denver, running 5 of these trials.
Enrollment posture brief
Registry condition diabetic-nephropathies
OPEN 6 | RECR 46% | LATE 1 | EARLY 8 | RANK #1315 | SPON 5
Volume-matched condition peers
Nearest open-share peer: B-cell Lymphoma (46% recruiting · 39 trials)
Diabetic Nephropathies lists 6 open slots (46% of 13 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Diabetic Nephropathies on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Diabetic Nephropathies recruits in line with its size-band peers.
6 of 13 indexed trials (46.2%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Diabetic Nephropathies research.
University of Colorado, Denver accounts for 5 of 13 trials (38.5%). 7 distinct sponsors appear on at least one study for this condition label.
-
Typical Diabetic Nephropathies enrolment sits around 96 participants.
Median target enrolment is 96 among the 13 trials that report a genuine target (sentinel values excluded). 7 of those (53.8%) plan for fewer than 100 participants.
-
Diabetic Nephropathies splits between interventional and observational designs.
9 interventional and 4 observational studies make up this index (69.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
13 total, page 1 of 1
Transformative Research in Diabetic Nephropathy
University of Pennsylvania
NCT02986984
Transformative Research in Diabetic Nephropathy 2.0
University of Pennsylvania
NCT07444203
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
Alessandro Doria
NCT06217302
Formoterol in Diabetes
Medical University of South Carolina
NCT07022418
Pathogenesis of Kidney Disease in Type 1 Diabetes: a Modern Kidney Biopsy Cohort (The PANDA Study)
University of Colorado, Denver
NCT05319990
Study of WAL0921 in Patients With Glomerular Kidney Diseases
Walden Biosciences
NCT06466135
MEtabolic and Renal Effects of AutoMAted Insulin Delivery Systems in Youth With Type 1 Diabetes Mellitus
University of Colorado, Denver
NCT03945747
A Pilot Study of Fenofibrate to Prevent Kidney Function Loss in Type 1 Diabetes
Alessandro Doria
NCT04929379
A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Diabetic Kidney Disease
Boehringer Ingelheim
NCT04750577
Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function
University of Colorado, Denver
NCT03618420
First-In-Human Study of GFB-024 in Healthy Overweight and Obese Participants, and Participants With Type 2 Diabetes
Goldfinch Bio
NCT04880291
Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes
University of Colorado, Denver
NCT03620773
Evaluation of Coffee Therapy for Improvement of Renal Oxygenation
University of Colorado, Denver
NCT03878277
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 5 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Diabetic Nephropathies records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Diabetic Nephropathies trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Diabetic Nephropathies page
13 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 Diabetic Nephropathies trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Colorado, Denver sponsors the most Diabetic Nephropathies trials on record, review their full trial history before evaluating a specific study. See University of Colorado, Denver's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Diabetic Nephropathies condition card totals 13 registered trials; most-linked intervention Placebo; top US site state Colorado. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.